Physician profile
Wendy E White
NPI 1922336114
$1,098.05
in general payments reported to CMS, 2019-2025
14 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $104 · 2021: $405 · 2022: $39.83 · 2023: $27.02 · 2024: $93.44 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $210.26 | 2019-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $196.26 | 2021 | |
| Amgen INC. | $181.51 | 2019-2024 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $120.98 | 2021 | |
| Lilly USA, LLC | $67.53 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $45.22 | 2019-2021 | |
| Dexcom, INC. | $44.68 | 2021-2024 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $39.51 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $36.68 | 2019 | |
| Insulet Corporation | $36.48 | 2020-2021 | |
| Valeritas, INC. | $32.43 | 2019 | |
| Medtronic Minimed, INC. | $31.78 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.71 | 2021 | |
| Beta Bionics, INC. | $27.02 | 2023 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.